[ad_1]
The FDA approved the use of Eli Lily as an emergency antibody drug, “USA”, which combines bamlanivimab and etesevimab to treat mild to moderate cases of corona in adults and children “12 years and older weighing 40 kg”, who have tested positive for the Corona virus and are at Significant risk of progression to severe corona, and the authorized use includes treatment for persons 65 years of age or older or for those with some chronic medical conditions.
Approval from the US Food and Drug Administration.
The Food and Drug Authority said in a statement on its website, in a clinical trial for Corona patients who are at high risk of developing the disease, an intravenous infusion of my medication resulted bamlanivimab Yetesevimab Together, they significantly reduced coronavirus-associated hospitalization and death within 29 days of follow-up compared to a placebo.
Intervals FDA Use of Bamlanivimab Yetesevimab From Eli Laila to patients who are hospitalized or require oxygen therapy due to Corona.
Treatment with use has not been studied. bamlanivimab Yetesevimab In hospitalized patients where treatment can produce monoclonal antibodies, such as bamlanivimab Yetesevimab, With worse clinical outcomes when administered to hospitalized coronavirus patients who require high flow oxygen or mechanical ventilation.
Eli lilly
The auctioned Eli lilly Combination antibody therapy to combat corona has received emergency use approval from the US Food and Drug Administration.
Data from the last phase of a trial in January showed that Lily’s combination treatment consisted of two antibodies, namely: bamlanivimab YetesevimabIt helped reduce the risk of hospitalization and death in Corona patients by 70%.
In a statement, Lilly said 100,000 doses were ready immediately and an additional 150,000 doses would be available during the first quarter.
The company added that it plans to cooperate with Amgen. Amgen To manufacture up to 1 million doses of etesevimab With bamlanivimab In mid 2021.
“Treatment is allowed for mild to moderate corona treatment in patients 12 years of age or older, who are at high risk of progressing to severe corona or hospitalization,” Lilly said.
Late last month, Leila’s company announced Lilly Its fourth-quarter earnings beat Wall Street estimates and posted $ 871.2 million in sales from the treatment.
